Clinical trials
Hematologic Malignancy clinical trials
Below are recruiting hematologic malignancy clinical trials, each written for real people, not researchers. We’re tracking 289 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT07670949Recruiting
68Ga-EV203 imaging for blood cancers
This trial uses a special imaging agent called 68Ga-EV203 to see where certain blood cancers (multiple myeloma, non-Hodgkin lymphoma, or acute myeloid leukemia) are located in the body. It helps doctors understand how the agent spreads and how safe it is.
Hangzhou, ZhejiangAges 18–75 - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07285668Recruiting
Special donor immune cells after stem cell transplant for high-risk blood cancers
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Madison, WisconsinAges 18–80 - NCT03537482RecruitingEarly Phase 1
Testing a new drug for blood cancers in adults
This early trial studies how safe and tolerable APG-2575 is, and how the drug moves through the body, in adults with certain relapsed or hard-to-treat blood cancers. It may help researchers learn whether the treatment could work better for people who have limited options.
Jacksonville, FloridaAges 18 years+ - NCT03557619RecruitingPhase 1
Venetoclax test in women with specific non-Hodgkin lymphomas
This Phase 1 study tests how venetoclax affects certain hormone pills (ethinyl estradiol and levonorgestrel) in women with different non-Hodgkin lymphomas. It’s mainly looking at safety and drug interactions, which could help guide treatment for people who need hormone-based contraception.
Detroit, MichiganAges 18 years+ - NCT04546945Recruiting
Test for CD56 in newly diagnosed blood cancers
This trial looks at a marker called CD56 in people who have been newly diagnosed with a blood cancer (a hematologic malignancy). The results may help doctors better understand the disease and guide future treatment choices.
AsyutAges Any age - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT06150469Recruiting
Inhaled aromatherapy for nausea from chemo
This trial tests if smelling a blend of essential oils can help reduce nausea and vomiting caused by chemotherapy in people with blood cancers. You would use a simple inhaler stick whenever you feel sick.
BrivéAges 18 years+ - NCT06206174RecruitingPhase 1/Phase 2
Study of TGRX-814 for blood cancers
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06326463RecruitingPhase 1
CAR T-cell therapy for CD70-positive blood cancers in children
This trial tests a special immune cell therapy (CAR T-cells) that targets a protein called CD70 on blood cancer cells. It is for children and young adults up to age 21 whose cancer has come back or hasn't gotten better with other treatments.
Memphis, TennesseeAges Up to 21 years - NCT06387082RecruitingPhase 1
Study of an investigational pill for certain leukemias
This study tests an experimental pill (HMPL-506) for people with certain types of leukemia (AML or ALL) that have not responded to standard treatments. The pill targets specific gene changes (MLL rearrangement or NPM1 mutation) to try to kill the cancer cells.
ChangshaAges 18 years+ - NCT06550102Recruiting
Drug response profiling for blood cancers
This study collects tumor samples from children and young adults with blood cancers to test how their cancer responds to different drugs. The goal is to find more effective treatments for each person.
Zurich, Canton of ZurichAges Up to 40 years - NCT07052370RecruitingPhase 1
New stem cell transplant for children with high-risk blood cancer
This trial tests a special stem cell transplant from a half-matched family donor, designed to reduce rejection and infection risk. It may include a targeted drug (blinatumomab) to help kill remaining cancer cells.
Memphis, TennesseeAges Up to 21 years - NCT07122674Recruiting
New PET scan for blood cancers
This study tests a new PET scan method (using a special tracer called 18F-Pentixafor) to see if it can better find and track blood cancers. It may help your doctors get more detailed images with less radiation.
Hangzhou, ZhejiangAges 18–80 - NCT07189117Recruiting
Study of cell metabolism in blood cancers
This study looks at how blood cancer cells use energy (metabolism) and how that affects the immune system. Researchers hope to find new ways to treat these cancers by understanding cell metabolism better.
BaselAges 18 years+ - NCT02134574Recruiting
Study of blood cancers in adults in southern France
This study follows adults who are being checked for a possible blood cancer, or who were recently diagnosed with a blood cancer within the last 6 months. It may help doctors understand the condition better and improve how early workups and care are organized.
MontpellierAges 18 years+ - NCT07172191Enrolling by invitation
Fecal transplant for adults with blood cancer and infections
This trial tests whether transplanting healthy donor bacteria (fecal microbiota) into the gut can help adults with blood cancers who have stubborn infections, C. diff, or complications after stem cell transplant. It may reduce dangerous germs and improve gut health.
Budapest, BudapestAges Any age - NCT05011422RecruitingPhase 1
Stem cell transplant using half-matched donor for kids with blood cancer
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
St Louis, MissouriAges Up to 30 years - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT06548958Recruiting
TBI and chemotherapy before a second stem cell transplant
This trial tests a combination of total body irradiation and two chemotherapy drugs as preparation for a second stem cell transplant in people with blood cancers that relapsed or didn't respond to the first transplant.
Suzhou, JiangsuAges 14–70
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Hematologic Malignancy trials by city
Studies with a site in or near these metro areas.
Hematologic Malignancy trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hematologic malignancy?
- Yes. Clin2 currently lists 289 recruiting hematologic malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematologic malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematologic malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.